Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions

Advanced Solid Tumors

Interventions

DRUG

HS-20093

All participants will receive intravenous infusion of HS-20093 at a dose of 8 mg/kg every 3 weeks (Q3W), with each treatment cycle lasting 21 days.

DRUG

Itraconazole

Participants will then take itraconazole capsules orally at 200 mg per dose during C2D17-C3D21

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY